Rani Therapeutics Holdings Inc at Needham Healthcare Conference (Virtual) Transcript
Before I get started, I want to give a big thank you to Needham for giving us the opportunity to present at this conference. My name is Talat Imran, and I'm the CEO of Rani Therapeutics, and I'm going to walk you through the Rani story.
I'll be making a number of forward-looking statements throughout the course of this presentation. Rani Therapeutics is a clinical-stage biotech company, and we're taking injectable biologics and turning them into pills. This is not a new idea. There have been many attempts that have preceded us primarily focused on delivering small peptides orally. The problem with that is ultra-low bioavailability.
So historically, less than 1% of the drug has been absorbed through these chemistry-based approaches with commensurately high variability, which is why, except for Novo Nordisk's oral semaglutide, there are really no approved oral biologics.
Rani has taken a completely orthogonal approach and developed a platform technology that works not only for peptides, but for monoclonal antibodies, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
